Victory Capital Management Inc. Has $12.74 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Victory Capital Management Inc. reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 17.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 81,328 shares of the company's stock after selling 16,957 shares during the period. Victory Capital Management Inc. owned 0.28% of Krystal Biotech worth $12,741,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of KRYS. Wilmington Savings Fund Society FSB bought a new stake in shares of Krystal Biotech during the 3rd quarter worth $40,000. Huntington National Bank raised its stake in Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company's stock valued at $104,000 after purchasing an additional 283 shares during the last quarter. KBC Group NV raised its stake in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company's stock valued at $117,000 after purchasing an additional 132 shares during the last quarter. Avanza Fonder AB acquired a new position in Krystal Biotech during the 4th quarter valued at $119,000. Finally, Blue Trust Inc. raised its stake in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

Shares of KRYS stock traded up $2.01 during mid-day trading on Friday, reaching $179.38. The company's stock had a trading volume of 153,585 shares, compared to its average volume of 284,750. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The company has a market cap of $5.17 billion, a P/E ratio of 59.99 and a beta of 0.87. The firm's 50-day moving average is $163.50 and its two-hundred day moving average is $173.90.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm's revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter last year, the company posted $0.30 EPS. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on KRYS. Citigroup upped their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Chardan Capital upped their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and a consensus target price of $220.00.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).